A systematic review highlights the potential of spectrin breakdown products as biomarkers for neuronal injury, suggesting a need for standardized methods.
SBDPs, such as SBDP120, 145, and 150, show promise as biomarkers of neuronal injury, although evidence is limited in some clinical conditions, however, their clinical applicability remains context-dependent and is currently limited by methodological heterogeneity. Standardized assays, larger cohorts, and longitudinal studies are needed to strengthen the existing promising evidence.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: